Martin-Mola Emilio, Balsa Alejandro
Department of Rheumatology, Hospital Universitario La Paz, Paseo de la Castellana 261, Madrid 28046, Spain.
Rheum Dis Clin North Am. 2009 Feb;35(1):183-99. doi: 10.1016/j.rdc.2009.03.009.
Infection is a frequent complication in rheumatoid arthritis (RA) and other autoimmune diseases. Since 2000, the spectrum of therapeutic possibilities (ie, biologic agents) for treating RA has expanded rapidly and many safety reports of patients treated with these drugs have been published. In most studies, biologics are associated with an increased incidence of infections with the use of tumor necrosis factor antagonists. Reported risks for developing infection differ among studies. This article provides an overview of which studies the authors consider the most relevant.
感染是类风湿关节炎（RA）和其他自身免疫性疾病中常见的并发症。自2000年以来，治疗RA的治疗选择范围（即生物制剂）迅速扩大，并且已经发表了许多使用这些药物治疗患者的安全性报告。在大多数研究中，生物制剂与使用肿瘤坏死因子拮抗剂导致的感染发生率增加有关。不同研究报告的感染发生风险有所不同。本文概述了作者认为最相关的研究。
